openPR Logo
Press release

Age-related Macular Degeneration Market Size was ~USD 9,500 Million in 2022, estimated DelveInsight

06-12-2024 10:26 PM CET | Health & Medicine

Press release from: ABNewswire

Age-related Macular Degeneration Market Size was ~USD 9,500

DelveInsight's 'Age-related Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034' report deliver an in-depth understanding of the Age-related Macular Degeneration, historical and forecasted epidemiology as well as the Age-related Macular Degeneration market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Explore the intricate details of the Age-related Macular Degeneration Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Age-related Macular Degeneration Market Forecast. Click here to stay ahead in healthcare innovation @ Age-related Macular Degeneration Market Size [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Age-related Macular Degeneration Market Report

* June 2024:- Stealth BioTherapeutics Inc. - A Phase 3, Double-Masked, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects Who Have Dry Age-Related Macular Degeneration (Dry AMD).
* June 2024:- Outlook Therapeutics Inc .- Safety and Effectiveness of ONS-5010 Compared to Lucentis Registered in Subjects With Neovascular Age-related Macular Degeneration; NORSE EIGHT. Multicenter, randomized, masked, controlled study of the safety and effectiveness of intravitreally administered ONS-5010.
* June 2024:- Hoffmann-La Roche - A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Portal).
* June 2024:- Kyowa Kirin Inc.- A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration.
* In the year 2022, the total prevalent cases of AMD were approximately 52,684,880 in the 7MM, which might increase at a decent CAGR by 2034.
* The US accounted for approximately 17,688,550 prevalent cases of AMD in the year 2022.
* The leading Age-related Macular Degeneration Companies such as Unity Biotechnology, Inc, PanOptica, Inc., Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA Inc, Outlook Therapeutics, Inc., Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Luxa Biotechnology, Gemini Therapeutics , and others.
* Promising Age-related Macular Degeneration Therapies such as NG101 AAV gene therapy, Iptacopan (LNP023), VOY-101 , and others.

Delve deep into the Age-related Macular Degeneration Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Age-related Macular Degeneration Market Forecast. Click here to shape the future @ Age-related Macular Degeneration Epidemiology Insights [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Age-related Macular Degeneration Overview

Age-related Macular Degeneration (AMD) is a medical condition that affects the macula, the central part of the retina responsible for sharp, detailed vision. It is a leading cause of vision loss in older adults. AMD comes in two main forms: dry (atrophic) and wet (neovascular or exudative).

Age-related Macular Degeneration Epidemiology Insights

* Total Age-related Macular Degeneration Prevalent Cases
* Total Age-related Macular Degeneration Age-specific Cases
* Total Age-related Macular Degeneration Diagnosed Prevalent Cases
* Total Age-related Macular Degeneration Diagnosed Dry AMD Cases by stages
* Total Age-related Macular Degeneration Geographic Atrophy Cases by Visual Impairment
* Age-related Macular Degeneration Type-specific Diagnosed Prevalent Cases

Navigate the complexities of the Age-related Macular Degeneration Market: Gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Age-related Macular Degeneration Market Forecast. Click here to get more insights @ Age-related Macular Degeneration Treatment Market [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Age-related Macular Degeneration Market Insights

Age-related Macular Degeneration is the most common cause of severe loss of eyesight among people aged 50 and older. It affects the central vision and, with it, the ability to see fine details. In AMD, a part of the retina called the macula get damaged. Medication can help reduce the progression of the illness and prevent vision loss.

Age-related Macular Degeneration Treatment Landscape

the best available treatment for AMD was photodynamic therapy-in which an intravenous drug (injected into a vein) and laser were used to seal off leaking blood vessels. Past studies have found that just 1 year after diagnosis, less than 15% of patients given this therapy alone retain 20/40 vision, and up to 40% decline to 20/200 vision. However, advances in medical research have identified the Vascular Endothelial Growth Factor (VEGF) as a key pathophysiological factor in the development of neovascular AMD, with an essential role in angiogenesis, vascular permeability, and inflammatory response. The introduction of anti-VEGF intravitreal injections has opened a new therapeutic window in the management of wet AMD, thus efficiently blocking the pathophysiological process of AMD, with a restoration of retinal morphology and the maintenance of its function.

Age-related Macular Degeneration Market Size

According to the DelveInsight analysis, the United States accounted for the highest market size, with approximately 50% of the market share of Dry age-related Macular Degeneration (AMD) as compared to other countries of the 7MM in the year 2022. The Age-related Macular Degeneration market size of the 7MM is anticipated to increase in the forecast period due to expected launch of emerging therapies in the 7MM.

Unlock insights into the Age-related Macular Degeneration Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Age-related Macular Degeneration Market Forecast. Click here @ Age-related Macular Degeneration Market Drivers and Barriers [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Age-related Macular Degeneration Therapies and Companies

* Eylea (aflibercept): Regeneron Pharmaceuticals
* Beovu(brolucizumab): Novartis
* Lucentis (ranibizumab): Roche
* Vabysmo (faricimab): Roche
* Susvimo (ranibizumab): Roche

Age-related Macular Degeneration Drug Market

The overall Age-related Macular Degeneration (AMD) Market is expected to boost due to rising prevalence cases over the globe and thus the surge in treatment options. Along with the expected launch of emerging therapies, the treatment market of Wet-AMD and Dry-AMD is supposed to boost in the forecasted period (2024-2034).

Scope of the Age-related Macular Degeneration Market Report

* Coverage- 7MM
* Age-related Macular Degeneration Companies- Unity Biotechnology, Inc, PanOptica, Inc., Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA Inc, Outlook Therapeutics, Inc., Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Luxa Biotechnology, Gemini Therapeutics, and others.
* Age-related Macular Degeneration Therapies- NG101 AAV gene therapy, Iptacopan (LNP023), VOY-101, and others.
* Age-related Macular Degeneration Market Dynamics: Age-related Macular Degeneration Market drivers and Age-related Macular Degeneration Market Barriers
* Age-related Macular Degeneration Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Age-related Macular Degeneration Unmet Needs, KOL's views, Analyst's views, Age-related Macular Degeneration Market Access and Reimbursement

Gain a strategic edge in the Age-related Macular Degeneration Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Age-related Macular Degeneration Market Forecast. Click here to lead in advancements @ Age-related Macular Degeneration Clinical Trials Assessment [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

1. Key Insights

2. Report Introduction

3. Wet AMD Market Overview at a Glance

4. Dry AMD Market Overview at a Glance

5. Wet AMD Market: Future Perspective

6. Executive Summary

7. Key Events

8. Disease Background and Overview

9. Epidemiology and Patient Population

10. Patient Journey

11. Marketed Drugs

12. Emerging Drugs of Wet AMD

13. Emerging Drugs of Dry AMD

14. AMD: Seven Major Market Analysis

15. Key Opinion Leaders' Views

16. Market Drivers

17. Market Barriers

18. SWOT Analysis

19. Market Access and Reimbursement of Wet AMD

20. Unmet Needs

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=agerelated-macular-degeneration-market-size-was-usd-9500-million-in-2022-estimated-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Age-related Macular Degeneration Market Size was ~USD 9,500 Million in 2022, estimated DelveInsight here

News-ID: 3536791 • Views:

More Releases from ABNewswire

Independent Filmmaker Jon Paul Breaks World Record with Award-Winning Martial Arts Short Film Dojo
Independent Filmmaker Jon Paul Breaks World Record with Award-Winning Martial Ar …
"Dojo" sets a new record with 495 International Film Awards, outshining high-budget productions. Jon Paul, an independent filmmaker, entrepreneur, and accomplished martial artist, has made cinematic history with his debut short film, Dojo [https://www.dojothefilm.com/]. The film has garnered an astounding 495 international awards, breaking the world record for the most awards won by a live-action fictional short film. Dojo, which Paul produced, wrote, and starred in, now surpasses the previous record
Coconut Water Market Revenue to Reach $22.91 Billion by 2029, 3X Growth in the Next 6 Years - Market Size, Share, & Trend Analysis 2023-2029 - Arizton
Coconut Water Market Revenue to Reach $22.91 Billion by 2029, 3X Growth in the N …
According to Arizton's latest research report, the global coconut water market [https://www.arizton.com/market-reports/coconut-water-market-size-analysis-2025] is growing at a CAGR of 20.01% during 2023-2029. Looking for More Information? Click: https://www.arizton.com/market-reports/coconut-water-market-size-analysis-2025 Report Summary: Market Size (2029): $22.91 Billion Market Size (2023): $7.67 Billion CAGR (2023-2029): 20.01% Market Size (Volume): 6.86 Billion Litre Historic Year: 2020-2022 Base Year: 2023 Forecast Year: 2024-2029 Market Segmentation: Product, Variant, Category, Packaging, Distribution Channel, and Geography Geographical Analysis: North America, Europe, APAC, Latin America, and Middle East & Africa Book the
UHMW PE MarketGrowth, Size, Opportunities, Top Manufacturers, Share, Trends, Key Segmentation, Regional Analysis, and Forecast to 2029
UHMW PE MarketGrowth, Size, Opportunities, Top Manufacturers, Share, Trends, Key …
The UHMW PE market is expanding due to its high abrasion resistance and low friction properties. Regional growth is significant in North America, Europe, and Asia-Pacific, driven by industrial and manufacturing demand. The UHMW PE market [https://www.marketsandmarkets.com/Market-Reports/ultra-high-molecular-weight-polyethylene-market-257883188.html?utm_source=abnewswire.com&utm_medium=referral&utm_campaign=uhmwpemarket] size is projected to grow from USD 2.2 billion in 2024 to USD 3.4 billion by 2029, registering a CAGR of 9.5% during the forecast period. The demand for UHMW PE is driven by
Non Small Cell Lung Cancer Pipeline Insights, Treatment Drugs, Emerging Therapies and Companies 2024
Non Small Cell Lung Cancer Pipeline Insights, Treatment Drugs, Emerging Therapie …
DelveInsight's, "Non-Small-Cell Lung cancer (NSCLC) Pipeline Insight, 2024," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Non-Small-Cell Lung cancer (NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options

All 5 Releases


More Releases for Macular

Macular Edema Treatment Market Growth Factors and Emerging Trends Forecast to 20 …
Global Macular Edema Treatment Market Analysis 2022-2028 Report provides strategists, marketers and senior management with the critical information they need to assess the global Macular Edema Treatment Market as it emerges from the Covid-19 shut down. The impact of Coronavirus (COVID-19) on global market has reinforced many trends already shaping the industry pre COVID-19, There is a long-term trend towards the repositioning of players as entertainment providers on multiple platforms. This
Macular Edema and Macular Degeneration Market Size, Analysis, Forecast to 2028 | …
Stratagem Market Insights have included the latest addition of a report titled Macular Edema and Macular Degeneration Market to its expansive repository. The report studies primary and secondary research in order to analyze the data effectively. The market study further also draws attention to crucial industry factors such as global clients, potential customers, and sellers, which instigates positive company growth. In order to gauge the turning point of the businesses,
Macular Pucker Treatment Market – Forecast to 2026
The findings reviewed by GME stated that the Global Macular Pucker Treatment Market would grow at a CAGR value of 6.9 percent from 2021 to 2026. The increasing rate of individuals above the age group of 50 with macular pucker issues drives growth of the macular pucker treatment market. Besides the increasing patient rate, launch of advanced treatment therapies and products have resulted in macular pucker treatment being one of
Macular Edema and Macular Degeneration Market Share, Trends and Analysis, Growth …
Macular edema is a condition in which the retinal layers around the fovea is accumulated by the fluid that leads to the vision impairment and also might lead to the vision loss. Macular edema can be of two types, namely cystoid macular edema and diabetic macular edema. In addition to this, the macular degeneration is a condition in which the loss of vision occurs due to the retinal damage and
Diabetic Macular Edema - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Diabetic Macular Edema - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Macular Edema - Pipeline Review, H1 2017, provides an overview of the Diabetic Macular Edema (Metabolic Disorders) pipeline landscape. Diabetic macular edema (DME) occurs when blood vessels in the retina of patients with diabetes
Growth Macular Edema Therapeutics Market: 2017 - 2025
Macula is oval yellowish area surrounding the center of retina in the eye. Macular edema is the state when fluid and protein start accumulating under macula resulting swelling in the eye. Due to this swelling, central vision of eye get distorted. Macular edema is classified into two types namely cystoids macular edema (CME) and diabetic macular edema (DME). The retina is the light-sensitive tissue at the back of the eye